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A B S T R A C T
Aurora A kinase is a master mitotic regulator whose functions are controlled by several regulatory interactions and post-translational modifications. It is frequently
dysregulated in cancer, making Aurora A inhibition a very attractive antitumor target. However, recently uncovered links between Aurora A, cellular metabolism and
redox regulation are not well understood. In this study, we report a novel mechanism of Aurora A regulation in the cellular response to oxidative stress through
CoAlation. A combination of biochemical, biophysical, crystallographic and cell biology approaches revealed a new and, to our knowledge, unique mode of Aurora A
inhibition by CoA, involving selective binding of the ADP moiety of CoA to the ATP binding pocket and covalent modification of Cys290 in the activation loop by the
thiol group of the pantetheine tail. We provide evidence that covalent CoA modification (CoAlation) of Aurora A is specific, and that it can be induced by oxidative
stress in human cells. Oxidising agents, such as diamide, hydrogen peroxide and menadione were found to induce Thr 288 phosphorylation and DTT-dependent
dimerization of Aurora A. Moreover, microinjection of CoA into fertilized mouse embryos disrupts bipolar spindle formation and the alignment of chromosomes,
consistent with Aurora A inhibition.
Altogether, our data reveal CoA as a new, rather selective, inhibitor of Aurora A, which locks this kinase in an inactive state via a “dual anchor” mechanism of
inhibition that might also operate in cellular response to oxidative stress. Finally and most importantly, we believe that these novel findings provide a new rationale
for developing effective and irreversible inhibitors of Aurora A, and perhaps other protein kinases containing appropriately conserved Cys residues.
1. Introduction
Aurora kinases are Ser/Thr kinases that play well-documented roles
in eukaryotes, where they control meiosis, mitosis and cell division [1].
Aurora kinases differ in relative expression levels, stability and sub-
cellular localization, the latter linked to single amino acid differences
that dramatically affect biological distribution and function [2–4]. In
vertebrates, the Aurora family of protein kinases are grouped into two
distinct sub-families composed of Aurora A and Aurora B and C [5].
Aurora kinases contain a conserved C-terminal kinase domain, which
phosphorylates substrates with a minimal R-X-S/T consensus motif
[6,7]. The Aurora kinase domain is itself regulated by a critical au-
tophosphorylation event in the activation loop [8–11], which is asso-
ciated with catalytic activation and timely execution of different phases
of mitosis [12–15] and meiosis [16]. During the cell cycle, Aurora A has
canonical roles in centrosome duplication, spindle bipolarity,
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chromosome segregation and spindle checkpoint maintenance [17],
which together contribute to fundamental processes such as cen-
trosomal and genomic stability and likely reflect the long-recognised
oncogenic properties associated with overexpressed Aurora A [18].
Interestingly, Aurora A has also recently been implicated in the control
of energy production in cancer cells through mitochondrial targeting
[19]. In contrast, Aurora B is a chromosomal passenger protein required
for the spindle assembly checkpoint and rate-limiting for cytokinesis in
cells [20]. Aurora C is most highly expressed in germ cells, where it can
functionally replace Auora B as a chromosome passenger protein [1].
Aurora A biology is controlled via targeted subcellular localization
mediated through the formation of dynamic protein complexes with
non-catalytic binding partners such as TPX2 [9,10,21–23], TACC3 [24]
and NMYC [25], which control distinct Aurora A signaling outputs.
Indeed, Aurora A/TPX2 holoenzyme complexes co-localise at the polar
end of spindle microtubules, where Aurora A is maintained in dynamic
pools alongside the mitoitc kinesin Eg5, which is localised by a C-
terminal motif in TPX2 [22,26,27]. Allosteric Aurora A activation on
the spindle is thought to occur by binding to microtubule-associated
proteins (which are also Aurora A substrates) such as TPX2 and TACC3
[28]. Mechanistically, Aurora A activation requires autopho-
sphorylation of Thr 288 (and possibly Thr 287), which drives the kinase
into the most catalytically-competent conformation [3,9,29]. Interest-
ingly, the TPX2 complex also protects Aurora A from Thr 288 depho-
sphorylation by PP1 and PP2A phosphatases in vitro [3,9], although
accumulating evidence suggests that the PP6 Ser/Thr phosphatase is
rate-limiting for mitotic dephosphorylation at this site in cells [27]. In
addition to TPX2, Aurora A is targeted to core protein co-factors, in-
cluding the centrosomal protein Cep192, the mitotic entry factor BORA
and the transcription factor NMYC [30], whose interaction with a
specific inactive Aurora A conformation is important for controlling
NMYC stability in cells, and the basis for new approaches to target
Aurora A output with drugs [30].
Structural analysis of Aurora A confirms the importance of activa-
tion loop dynamics for activity and binding-partner interactions [24].
Phosphorylation, as well as TPX2 binding, stabilise the activation se-
gement in an appropriate conformation for catalysis, and distinct
Aurora A conformations can also be induced and/or stabilised by a huge
variety of chemical small molecules [13,14,31–34]. Such compounds
have been extremely useful to validate dozens of cellular Aurora A
substrates [6,13], which include cell cycle-regulated kinases such as
PLK1 [14,35].
In a clinical context, overexpression of Aurora A is frequently de-
tected in human malignancies, including leukemia, breast, prostate and
colon cancers [18,36,37], and lower overall survival in patients with
colorectal cancer correlates with increased levels of Aurora A [38]. For
these reasons, Aurora A has been pursued for decades as a target for the
development of anti-cancer therapeutic agents, some of which show
potential in the clinic. Beginning with MLN8054 [39], a number of
potent, and highly selective, ATP-competitive small molecule inhibitors
of Aurora A have been reported, with several advancing to phase II
clinical trials, and MLN8237 (alisertib) [40] proceeding to phase III
evaluation after demonstrating promising activity in a variety of tu-
mour settings [41,42]. Interestingly, while numerous ATP-competitive
and allosteric ligands for Aurora A have been developed, some of which
can specifically target the highly similar Aurora A and Aurora B, no
type IV (covalent) inhibitors of Aurora kinases have yet been reported.
Coenzyme A (CoA) is essential for the viability of all living cells
where it is a major regulator of cellular metabolism [43,44]. The CoA
biosynthetic pathway is conserved in prokaryotes and eukaryotes and
requires five enzymatic steps, involving sequential conjugation of
pantothenic acid (vitamin B5), cysteine and ATP [44]. The presence of a
nucleotide moiety and a highly reactive thiol group permits broad di-
versity in biochemical reactions, which CoA employs to activate car-
bonyl-containing molecules and to generate covalent thioester deriva-
tives such as Acetyl CoA, Malonyl CoA and 3-hydroxy-3-methylglutaryl
CoA. Intracellular levels of CoA and its thioester-derivatives are tightly
regulated by a variety of stimuli, including hormones, nutrients, me-
tabolites and stresses [43,44]. The main rate-limiting enzyme in CoA
biosynthesis is pantothenate kinase which initiates the biosynthetic
pathway [45]. Furthermore, the activity of the last enzyme in the
pathway, CoA synthase, is regulated by extracellular stimuli and stress
response [46–49].
CoA and its thioester derivatives are strategically positioned at the
crossroads of cellular anabolic and catabolic pathways, controlling the
Krebs cycle, ketogenesis, the biosynthesis of proteins, lipids and cho-
lesterol, oxidation of fatty acids and degradation of amino acids. In
addition, they are also involved in the regulation of gene expression and
cellular metabolism via post-translational modifications, such as pro-
tein acetylation, butyrylation, malonylation and succinylation.
Abnormal biosynthesis and homeostasis of CoA and its derivatives is
associated with various human pathologies, including neurodegenera-
tion, cancer, metabolic disorders and cardiac hypertrophy [44].
Protein CoAlation is a recently described post-translational mod-
ification (PTM) that involves covalent modification of cysteine residues
by CoA [50]. New research tools and methodologies have revealed
protein CoAlation as a widespread and reversible PTM involved in
cellular redox regulation [51]. To date, more than one thousand pro-
teins have been found to be CoAlated in a variety of prokaryotic and
eukaryotic cells [50,52]. Protein CoAlation occurs at a low level in
exponentialy growing cells, but is strongly induced in reponse to var-
ious oxidising agents, including H2O2, diamide, menadione and t-butyl
hydroperoxide. Protein CoAlation alters the molecular mass, charge,
and activity of modified proteins, and is thought to protect them from
irreversible over-oxidation.
The presence of exposed cysteine residues on the surface of proteins
provides a simple, sometimes reversible, mechanism for post-transla-
tional modification of cell signaling proteins in response to a wide
variety of redox conditions. Most protein classes contain surface-ex-
posed Cys residues, and for the protein kinase superfamily, this
knowledge has been exploited to develop covalent (usually irreversible)
ATP-dependent kinase inhibitors with clinical utility [53,54]. Interest-
ingly, oxidative stress has marked effects on the cell cycle and pro-
liferation [55], and redox regulation of signaling-active components
such as tyrosine phosphatases [56] and CDC25 [57] contribute to
redox-regulated cell cycle checkpoints. More recently, the effects of
oxidative stress on abnormal spindle dynamics have been correlated
with Aurora A inhibition [58]. However, whether CoA modifies and/or
regulates protein kinases currently remains unknown.
In this study, we report Aurora A inhibition through a covalent in-
teraction with CoA. We found that CoA is a specific ATP-competitive
Aurora A inhibitor in vitro, and employed a combination of biochemical,
structural, mass spectrometry and cellular studies to confirm a pre-
ferential mode of CoA binding to the active, phosphorylated, Aurora A
conformation. Structural validation of the CoA binding mode confirms
that it exploits Thr 217 in the ATP binding site, a locus that distin-
guishes Aurora A from Aurora B [31,40], to maintain a unique inter-
action with the 3′-phospho-ADP moiety of CoA, positioning it for for-
mation of an unprecedented covalent bond between the pantetheine
thiol and Cys 290, a remote, but highly conserved, Aurora A residue
located in the activation loop. In support of this model, covalent
modification of Aurora A by CoA was shown to be stimulated in human
cells by oxidising agents, which also induced phosphorylation at Thr
288 and DTT-dependent dimerization of Aurora A. Furthermore, mi-
croinjection of CoA in mouse oocytes perturbed spindle formation and
chromosome alignment in vivo. Taken together, our data reveal Aurora
A as a novel target of the key metabolic regulator CoA, and opens the
door for the development of a new class of small molecule inhibitor that
exploits a ‘dual-anchor’ mechanism, bridging the Aurora A ATP-binding
site and the activation segment.
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2. Results
2.1. Kinase profiling screen with coenzyme A reveals specific inhibition of
Aurora A
CoA and ATP share an ADP moiety, which we hypothesised might
lead to a serendipitous modulation of the activity of protein kinases by
CoA. We tested this notion in a human kinome-wide activity-based
screen (MRC National Centre for Protein Kinase Profiling, University of
Dundee). Profiling of 117 protein kinases with CoA, dephospho-CoA
(dpCoA) and ADP provided clear evidence that CoA is a relatively se-
lective inhibitor for human Aurora A (Fig. 1A and Table 1). Moreover,
CoA inhibited Aurora A with marked selectivity (87% Aurora A in-
hibition at 100 μM, n=3) when compared to ADP, a very non-specific
kinase inhibitor that operates based on its close similarity to ATP. Only
a few other kinases, including the tyrosine kinases SRC and YES, were
inhibited ≤50% by CoA under these conditions. Interestingly, inhibi-
tion of Aurora B by CoA was also detected (46% inhibition at 100 μM
compound), while Aurora C was not present in the screen (Table 1).
dPCoA, which lacks the 3′-phosphorylated nucleotide, exhibited inter-
mediate specificity between CoA and ADP, raising the possibility that
both the pantetheine and 3′-phosphate moieties of CoA could be im-
portant for optimal inhibition of Aurora A (Fig. 1A). Further analysis
confirmed that CoA inhibits active Thr 288 phosphorylated (re-
combinant) Aurora A with an IC50 of 5 μM in the presence of 5 μM ATP
nucleotide in vitro (Fig. 1B). Using CoA Sepharose as an affinity matrix,
we confirmed that endogenous Aurora A present in exponentially
growing human HepG2 cells interacts specifically with conjugated CoA,
when compared to beads alone (Supplementary Fig. S1). Furthermore,
bound Aurora A was readily eluted from CoA Sepharose with an excess
of CoA.
Next, we quantified the binding kinetics of CoA, dpCoA, ADP and
ATP for catalytically active (Thr 288 phosphorylated) and catalytically
inactive (non-phosphorylated) forms of Aurora A. A Lanthascreen Eu
Kinase FRET Binding Assay was employed to evaluate the interaction of
CoA with Aurora A, and tease apart any molecular contributions made
by the pantetheine tail and nucleotide 3′-phosphate. We found that the
displacement curves for CoA and dpCoA were biphasic, indicating the
presence of two potential binding sites with higher and lower affinities
towards CoA (Fig. 1C). Bacterially expressed Aurora A proteins auto-
phosphorylate, resulting in a heterogeneous mixture containing active
and inactive Aurora A as a result of sub-stoichiometric phosphorylation
of different sites [14]. Importantly, treatment of bacterially expressed
Aurora A with protein phosphatase 1, which results in Thr 288 de-
phosphorylation [9], removed the high affinity-binding site, confirming
that this was related to the activation (phosphorylation) state of the
kinase (Fig. 1D). We next determined the affinity of interaction by ti-
trating Aurora A with CoA, dpCoA and ADP, and compared them with
values obtained from in vitro kinase (phosphotransferase) assays
(Table 2). Under the assay conditions used, the apparent IC50 for the
interaction of active Aurora A with CoA and dPCoA were 82 nM and
294 nM, respectively, whilst the IC50 value for ADP was approximately
177 μM. Taken together, these results clearly demonstrate that CoA and
dpCoA preferentially bind to the active (Thr 288-phosphorylated) form
of Aurora A, and suggest an involvement of the pantetheine tail and the
3′-phosphate of CoA in mediating a potentially specific interaction with
Aurora A.
2.2. Biophysical and structural analysis of the Aurora A:CoA complex
To confirm the interaction between CoA and Aurora A, we pre-in-
cubated phosphorylated Aurora A (containing pThr 288) with a molar
excess of CoA or dPCoA and analysed the complexes using intact mass
spectrometry (MS). Upon incubation, a sub-stoichiometric shift was
observed for each of the differentially phosphorylated intact Aurora A
species present in the preparation, consistent with the formation of
phosphorylated Aurora A adducts, each containing a single molecule of
CoA or dPCoA (Fig. 1E). We also evaluated effects of CoA and dPCoA on
the gas-phase conformation of Aurora A under native MS conditions
using Ion Mobility Mass Spectrometry (IM-MS), which is a recently-
developed approach that can be used to probe kinase conformational
dynamics [69]. The calculated cross-sectional (CCS) area of intact
Aurora A (nm [2]) in both 14+ and 15+ charge states increased after
pre-incubation with both CoA or dPCoA, consistent with their ability to
bind to Aurora A and induce a conformational change. The increase in
Aurora A CCS upon binding of either CoA or dPCoA, suggests that it is
the covalent attachment of the CoA pantetheine tail that drives the
conformational change in Aurora A (Fig. 1F).
To gain further insight into the binding mode of CoA for active
Aurora A, we next determined the crystal structure of the complex to
2.5 Å resolution (Table 3, Fig. 1G). As predicted, CoA occupies the
canonical ATP binding site of Aurora A, between the N-lobe and C-lobe
of the kinase. Remarkably, the extended CoA pantetheine moiety
stretches away from the ATP site towards the kinase activation loop,
forming a disulfide bond with the side chain of Cys 290 adjacent to Thr
288, the phosphorylated residue (Fig. 1H). Unexpectedly, the pan-
tothenic acid moiety of CoA interacts with the tip of the Gly-rich loop
(aa142-145) and displaces it from the position found in Aurora A/ADP
complexes, consistent with our IM-MS data. Interestingly, the 3′ phos-
phate group of CoA is also ideally positioned to form an H-bond with
the side chain of Thr 217, which is evolutionary conserved in vertebrate
Aurora A, but not Aurora B [31,40]. Our crystal structure of Aurora A/
CoA was consistent with independent molecular modelling of Aurora A
bound to CoA, based on a previously determined structure of Aurora A/
ADP (Supplementary Fig. S2). The structure employed for modelling
(PDB code 1OL7), was chosen based on previous knowledge that the
side chain of Cys 290 is in a potentially suitable position to react che-
mically with the pantetheine tail of CoA. Importantly, most features of
Fig. 1. Coenzyme A binds directly to Aurora A and inhibits catalytic activity. (A) Kinase profiling screen reveals selective inhibition of Aurora A by CoA. The
effect of CoA, dpCoA and ADP on the activity of 117 kinases was assayed using a radioactive filter-binding assay at the International Centre for Kinase Profiling,
Dundee University. Each compound was tested at 100 μM final concentration in the presence of the indicated concentrations of ATP for each kinase (Table 1).
Schematic structures of the tested compounds are shown above. (B) CoA inhibits Aurora A in vitro. Kinase activity of recombinant full-length His-Aurora A was
assayed by measuring incorporation of γ33P-ATP into myelin basic protein in the presence of 5 μM ATP and an 11-point serial dilution of CoA. (C) Analysis of binding
kinetics of CoA, dpCoA, ADP and ATP towards active (pT288-phosphorylated) Aurora A using a Lanthascreen Eu Kinase Binding assay (D) CoA preferentially binds to
the active, pT288 phosphorylated form of Aurora A, when compared to the catalytically inactive dephosphorylated kinase. Dephosphorylation of His-Aurora A was
carried out in the presence of recombinant PP1 phosphatase. (E) Intact mass analysis of phosphorylated Aurora A incubated with CoA in the absence of DTT. Covalent
incubation of CoA with Aurora A generates a population of phosphorylated Aurora A (pAurora A) alongside covalent adducts containing an extra mass attributable to
CoA (pAurora A + CoA). (F) Ion Mobility spectra and calculated cross sectional area (TWCCSN2→He) for [M+14H]14+ and [M+15H]15+ ions of pT288 Aurora A
measured in the absence (black line) or presence of CoA (red lines) or dephospho-CoA (blue lines). Overlapping conformations of Aurora A are shown, the more
extended of which have an increased mean cross sectional area associated with the presence of CoA and dephospho-CoA. (G) Crystal structure of Aurora A (teal) in
complex with CoA (pink). (H) Upper panel, magnified view of CoA and its interactions with Aurora A, highlighting the side chains of Thr 217 and Cys 290, which
forms a covalent bond with CoA. Lower panel, superposition of Aurora A/CoA with Aurora A/ADP (PDB code 1OL7), showing the shifted position of the Gly-rich loop
(black arrow) and the equivalent position of Cys 290 (red arrow). Note that the side chain of Cys 290 was modelled without the sulfur atom in the Aurora A/ADP
structure, due to weak electron density. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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the experimental crystal structure were predicted by this model, in-
cluding the specific interaction of the 3’-phosphate group of CoA with
the side chain of Thr 217. One exception is the experimentally up-
shifted position of the Gly-rich loop in the presence of CoA, which was
unexpected based on the model, in which the Gly-rich loop resides in a
canonical position, packed against the ADP phosphates.
Table 1
Kinase profiling of CoA, dpCoA and ADP. The ability of CoA, dpCoA or ADP
(100 μM final concentration of each compound and the indicated concentra-
tions of ATP) to inhibit the phosphotransferase activity of 117 kinases was
determined using a radioactive filter-binding assay at the International Centre
for Kinase Profiling, DSTT, University of Dundee. Kinase activity in the absence
of inhibitor is taken as 100%.
Kinase CoA ADP dpCoA ATP in assay (μM)
ABL 111.2 22.9 98.0 5
AMPK 90.8 54.1 75.9 50
ASK1 129.1 70.2 88.6 50
Aurora A 13.4 38.0 29.9 5
Aurora B 54.3 47.8 55.1 20
BRK 114.1 41.3 83.1 20
BRSK1 110.4 42.8 96.4 20
BRSK2 114.7 52.4 88.8 50
BTK 67.9 18.2 30.6 50
CAMK1 123.6 80.1 125.6 50
CAMKK 97.4 52.9 71.4 20
CDK2-Cyclin A 93.2 26.3 81.1 20
CHK1 122.6 47.6 78.8 20
CHK2 88.9 43.2 56.0 20
CK1δ 80.8 57.6 80.4 20
CK2α 80.1 5.4 39.8 5
CLK2 108.9 33.9 80.1 5
CSK 92.6 18.5 54.9 20
DAPK1 106.2 10.3 64.4 5
DYRK1A 93.1 75.9 90.2 50
DYRK2 102.4 42.4 77.0 50
DYRK3 95.1 16.2 91.2 5
EF2K 67.1 86.2 103.0 5
EPH-A2 102.0 45.0 99.2 50
EPH-A4 114.6 32.5 75.6 50
EPH-B1 116.9 11.6 80.0 20
EPH-B2 117.3 14.3 91.1 20
EPH-B3 104.2 18.0 94.4 20
EPH-B4 106.8 9.8 62.1 50
ERK1 118.2 67.7 114.0 5
ERK2 119.7 54.4 81.7 20
ERK8 101.4 16.6 38.5 5
FGF-R1 60.0 41.7 31.4 20
GCK 108.8 56.5 71.2 20
GSK3β 94.7 18.2 72.1 5
HER4 100.5 29.1 75.7 5
HIPK1 115.3 31.7 92.8 20
HIPK2 153.3 16.5 73.4 5
HIPK3 123.1 34.2 91.5 20
IKKβ 90.5 26.6 48.0 5
IKKε 125.2 73.8 91.4 50
IRAK4 89.1 82.1 74.8 20
JAK2 105.5 7.1 62.5 5
JNK1 85.4 53.9 82.4 20
JNK2 93.9 57.3 76.1 20
JNK3 101.3 58.6 63.2 20
Lck 100.4 35.1 69.0 50
LKB1 103.3 71.0 81.1 20
MAPKAP-K2 93.1 53.0 81.7 20
MAPKAP-K3 98.4 25.7 63.0 20
MARK1 95.3 28.1 68.0 20
MARK2 93.1 25.0 81.5 20
MARK3 88.9 14.8 46.2 5
MARK4 87.7 49.1 86.6 50
MEKK1 96.3 68.1 105.8 20
MELK 76.3 63.5 104.0 50
MINK1 106.3 49.4 103.9 50
MKK1 107.2 16.4 52.3 5
MKK2 103.0 35.4 53.0 5
MKK6 88.6 39.1 88.2 50
MLK1 109.9 41.4 76.0 20
MLK3 70.2 46.8 61.9 20
MNK1 150.3 60.7 84.2 50
MNK2 137.5 41.2 87.1 50
MSPK1 101.8 94.1 101.7 50
MSK1 106.4 53.3 70.5 20
MST2 118.8 40.5 72.5 20
MST4 107.0 56.9 89.7 20
NEK2α 148.5 42.1 100.4 50
Table 1 (continued)
Kinase CoA ADP dpCoA ATP in assay (μM)
NEK6 118.4 26.6 69.6 50
NUAK1 98.3 32.4 68.3 20
p38α MAPK 112.5 60.3 87.7 50
p38β MAPK 159.6 51.1 94.5 20
p38δ MAPK 128.0 37.3 71.3 5
p38γ MAPK 127.2 26.0 65.9 5
PAK2 88.8 90.3 111.9 20
PAK4 69.9 73.8 75.9 5
PAK5 70.6 79.5 86.0 20
PAK6 98.4 78.4 100.7 20
PDK1 113.3 23.3 91.2 20
PHKγ1 105.1 75.6 90.9 50
PIM1 103.0 46.1 97.7 20
PIM2 111.0 9.8 62.9 5
PIM3 121.7 36.1 96.7 20
PKA 98.9 27.8 81.3 20
PKCα 104.2 38.6 76.8 5
PKCβ 118.3 79.2 105.1 50
PKCα 78.1 76.5 88.9 20
PKCζ 99.3 37.7 89.9 5
PKCγ 70.2 71.9 66.4 20
PKD1 111.9 56.2 104.3 50
PLK1 101.3 52.2 100.0 5
PRAK 99.7 15.2 77.7 20
PRK2 71.3 20.8 67.5 5
RIPK2 131.4 46.0 88.4 20
ROCK 2 94.3 57.8 96.4 20
RSK1 97.2 58.5 98.9 50
RSK2 96.5 47.9 62.9 50
S6K1 89.1 35.5 30.5 20
SGK1 102.8 38.7 74.3 20
SmMLCK 92.1 73.0 91.3 20
Src 43.8 31.8 8.9 50
SRPK1 116.3 60.9 89.1 50
STK33 71.8 54.6 83.3 50
SYK 98.3 70.9 105.9 20
TAK1 115.3 15.8 79.6 5
TAO1 113.2 34.0 98.3 20
TBK1 106.3 95.1 109.6 50
TIE2 93.0 33.1 83.4 20
TTK 101.3 54.7 75.8 20
YES1 49.0 18.6 11.5 20
ZAP70 89.7 13.2 79.8 5
IGF-1R 93.0 – – 5
IR 100.0 – – 20
IRR 92.0 – – 5
TrkA 104.0 – – 20
VEGFR 81.0 – – 20
Table 2
CoA preferentially binds to active, T288 phosphorylated Aurora A. The
binding of T288 phosphorylated Aurora A (‘active’), or unphosphorylated
Aurora A (‘inactive’), was assessed for each compound and the inhibitory
constants were calculated. The data confirm that both the pantetheine and the
3′-phosphate of CoA participate in the interaction between Aurora A and CoA.
Compound Aurora A (active)
IC50 (μM), binding
assay
Aurora A (inactive)
IC50 (μM), binding
assay
Aurora A (active)
IC50 (μM), activity
assay
ATP 0.2 3.0 –
ADP 0.17 1.3 54
dpCoA 0.0003 >100 17
CoA 0.00001 0.28 5
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2.3. Aurora A is CoAlated on Cys 290 in vitro
The electron density map unambiguously supports the formation of
a covalent bond between the sulfur atoms in the side chain of Cys 290
and pantetheine thiol of CoA (Fig. 2A). To investigate the contribution
of this bond to the interaction, we employed a validated in vitro CoA-
lation assay [50]. Here, recombinant Aurora A was pre-incubated with
CoA, and the reaction mixture separated by SDS-PAGE under non-re-
ducing conditions followed by immunoblotting with a monoclonal anti-
CoA antibody. As shown in Fig. 2B, CoA interacts with Aurora A in a
DTT-sensitive manner, suggesting a thiol-dependent covalent mode of
binding. Ponceau staining of immunoblotted samples revealed that the
mobility of Aurora A was retarded when CoA disulfide was present in
the reaction mixtures. The addition of DTT completely abolished the
observed electrophoretic mobility shift, indicating the formation of
CoA–Aurora A mixed disulfides. LC-MS/MS analysis was employed to
map CoA-modified cysteine(s) of in vitro CoAlated Aurora A. This
analysis revealed that Cys290 is CoAlated in the RTpTLC290GTLDYPP-
EMIEGR peptide (Supplementary Fig. S3A), confirming the co-existence
of Thr 288-phosphorylated (active) Aurora A and Cys 290-CoA in vitro.
We also examined whether binding of the 3′-phosphate ADP moiety of
CoA to the Aurora A ATP binding pocket primes the pantetheine thiol
for disulfide bond formation with Cys 290 in the activation loop. In vitro
CoAlation of Aurora A was carried out with 100 μM CoA and increasing
concentrations of ATP (0–10 mM). Aurora A CoAlation gradually de-
creased in the presence of increasing concentrations of ATP, and was
completely abolished by inclusion of 1mM DTT (Fig. 2C). These ob-
servations suggest that occupancy of the ATP binding pocket by the 3′-
phosphate ADP moiety of CoA is a pre-requisite for covalent mod-
ification of Aurora A (see below).
Aurora A has two surface-exposed cysteine residues present in the
kinase domain: Cys 290 in the activation loop and Cys 393 in the C-
terminal regulatory region [65]. Mutational analysis allowed us to de-
monstrate that covalent modification of the Cys290Ala mutant by CoA
was dramatically reduced (by>95%) in comparison to wild-type Aurora
A, while no binding was detected with the double Cys290/393Ala mu-
tant (Fig. 2D–F). The dose-dependency of inhibition of active Aurora A
by CoA was also examined in the absence and presence of a reducing
agent (Fig. 2G). Aurora A was inhibited by CoA under both experimental
conditions. However, the IC50 value (CoA) was an order of magnitude
higher in the presence of DTT (47 μM), when compared to that obtained
in the absence of DTT (5 μM). To explore the mode of regulation further,
we tested the inhibitory effect of desulfo-CoA on Aurora A kinase ac-
tivity. In this analogue of CoA, the reactive SH group at the end of the
pantetheine tail is absent and unable to covalently modify Aurora A.
Consistently, the dose response inhibition curve for desulfo-CoA was also
shifted, resulting in a significantly higher IC50 value for Aurora A (160
μM), confirming the involvement of the CoA thiol group in the specific
inhibition of Aurora A kinase activity (Fig. 2H).
2.4. The role of Thr 217 in mediating a selective interaction between Aurora
A and CoA
We next sought to identify the basis of selectivity of CoA for Aurora
A over other protein kinases. To do this, we focussed on the closely
related Aurora A and B kinases, which share 70% sequence identity in
the kinase domain (Fig. 3A). The putative hydrogen bond between the
–OH side chain of Thr 217 in Aurora A and the 3′-phosphate of the
ribose ring of CoA (Fig. 1H) was of particular interest since Thr 217 is
known to contribute to the specificity of MLN8054, a selective Aurora A
inhibitor [40], whereas the corresponding residue Glu 177 in Aurora B
prevents compound binding, likely due to electrostatic repulsion
[31,40]. We compared covalent modification of Aurora A and Aurora B
using an in vitro CoAlation assay (Fig. 3B, D). This analysis revealed
strong CoAlation of Aurora A, while Aurora B was CoAlated at an ex-
tremely low level under optimal Aurora A assay conditions. Mutational
analysis showed that the Thr217Glu mutant of Aurora A exhibits sig-
nificantly reduced CoA binding compared to the wild-type kinase
(Fig. 3C). In contrast, a reciprocal Glu177Thr Aurora B mutant protein
exhibited strong binding to CoA (Fig. 3E). Together, these data indicate
that both the 3′-phosphate ADP moiety and the thiol group of CoA are
involved in mediating specificity-determining interactions with Aurora
A via targeting of Thr 217 and Cys 290 respectively.
2.5. Thermal shift-based detection of the Aurora A/CoA interaction
To probe thermal effects of CoA in the presence and absence of DTT,
we profiled Aurora A ligand binding in solution (Fig. 3F). WT Aurora A
is phosphorylated and catalytically active, whereas D274 N Aurora A
cannot bind to ATP and therefore remains dephosphorylated after iso-
lation from bacteria [7]. In contrast, C290A Aurora A is catalytically
active, but lacks the thiol-containing Cys residue in the kinase activa-
tion segment (Fig. 3A), while T217E Aurora A mimics Aurora B by
swopping a polar Thr for a charged Glu (see above). Thermal melting
profiles [60] for each protein were obtained in the presence and ab-
sence of DTT, ATP, CoA or the kinase inhibitor MLN8237. Binding of
ATP, CoA and MLN8237 induced a marked change in thermal stability
of WT Aurora A, which was dependent on non-reducing conditions in
the case of CoA, and entirely consistent with our findings employing
Aurora A isolated from human cells (Fig. 2B). Interestingly, CoA was
still able to interact with kinase-dead D274 N (inactive) Aurora A in a
DTT-dependent manner, although the interaction of this mutant with
Mg-ATP was severely blunted, as expected (green bars). In contrast,
C290A Aurora A still bound to ATP, but was deficient in CoA-induced
thermal stabilization (red bars). Finally, a CoA-induced thermal shift
was completely abolished in the T217E Aurora A mutant, in contrast to
stabilization by either ATP or MLN8237, confirming the importance of
a Thr in Aurora A for CoA binding.
Table 3
Data collection and refinement statistics.
Aurora A 122–403/CoA
Data collection
Space group P6122
Cell dimensions
a, b, c (Å) 80.89, 80.89, 173.34
α, β, γ (°) 90.00, 90.00, 120.00
Resolution range (Å) 44.57–2.50 (2.54–2.50)a
Rmerge (%) 8.58 (171)
I/σI 21.92 (1.61)
Completeness (%) 100 (100)
Redundancy 17.59 (15.07)
Refinement
Resolution (Å) 44.57–2.50
No. reflections 12263
Rwork/Rfree 20.44/25.21
No. atoms
Protein 2102
Hetero 73
Water 26
Mean B-factors
Protein 69.90
Hetero 77.39
Water
Wilson B-factor
69.30
70.56
r.m.s. deviations
bond lengths (Å) 0.013
bond angles (°)
MolProbity analysis
All-atom clash-score
1.23
9.17
Rotamers outliers (%)
0
Ramachandran outliers (%) 0
Ramachandran favoured (%) 95.06
MolProbity score 1.83
a Values in parentheses are for highest-resolution shell.
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Fig. 2. CoA reversibly binds to Aurora A in an ATP-competitive manner through Cys 290. (A) Electron density around the pantotheine tail region of CoA and
Cys 290 of Aurora A, 2Fo-Fc map contoured at 1 σ. (B) Aurora A is covalently modified by CoA in a DTT-sensitive manner. In vitro CoAlated Aurora A was separated
by SDS-PAGE in the presence or absence of DTT and immunoblotted with anti-CoA antibody. The membrane was stained with Ponceau red to visualize total Aurora
A. (C) Binding of CoA to the ATP-binding pocket is required to facilitate covalent modification of Aurora A by CoA. In vitro CoAlation of Aurora A was carried out in
the presence of 100 μM CoA and the indicated concentration of ATP. Generated samples were separated by SDS-PAGE in the presence or absence of DTT and
immunoblotted with anti-CoA and anti-Aurora A antibodies. (D) WT Aurora A is efficiently CoAlated by CoA in vitro. (E) The C290A Aurora A mutant exhibits
significantly reduced binding of CoA when compared to WT Aurora A. (F) The C290/393A Aurora A mutant is not covalently modified by CoA in vitro. In vitro
CoAlation of WT Aurora A, C290A and C290/393A mutants was performed with the indicated concentration of CoA. The reaction mixtures were separated by SDS-
PAGE and immunoblotted with anti-CoA and Aurora A antibodies. (G) The inhibitory effect of CoA towards Aurora A is reduced by DTT. Recombinant His-Aurora A
was used to determine the IC50 value for CoA in the presence or absence of 1 mM DTT. (H) Reduced inhibitory effect of desulfo-CoA compared to CoA. Desulfo-CoA
lacks the reactive SH group at the end of the pantetheine tail. (For interpretation of the references to color in this figure legend, the reader is referred to the Web
version of this article.)
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Fig. 3. Specificity of Aurora A interaction with CoA is controlled by Thr 217. (A) Amino acid conservation in vertebrate Aurora kinases. Thr 217 defines Aurora
A, and is changed to a Glu residue in Aurora B and C. Cys 290 (boxed) is invariant in all Aurora kinases, and lies in the activation segment adjacent to the
phosphorylated Thr 288 (human Aurora A numbering). (B) In vitro CoAlation of Aurora A. (C) In vitro CoAlation of Aurora A is abolished in the Thr217Glu mutant.
(D) In vitro CoAlation is not detected with Aurora B. (E) The Glu161Thr Aurora B mutant is efficiently CoAlated. Experiments were performed with the indicated
concentration of CoA. Reaction mixtures were separated by SDS-PAGE and immunoblotted with anti-CoA, Aurora A or Aurora B antibodies. (F) A thermal shift assay
was employed to evaluate Aurora A binding to 5 mM ATP, 5 mM CoA or 0.1 mM MLN8237, in the presence and absence of 1 mM DTT, as indicated. Assays were
performed with T 288 phosphorylated, active, Aurora A (open bars), kinase-dead, dephosphorylated Aurora A (Asp274Asn, green bars), Cys290Ala Aurora A (red
bars) or Thr217Glu Aurora A (blue bars). Mean ΔTm values ± SD (n= 3) were calculated by subtracting the control Tm value (buffer, no addition) from the
measured Tm value. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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2.6. Binding of TPX2 protects Aurora A from covalent modification and
inhibition by CoA
In vertebrates, TPX2 enhances Aurora A autophosphorylation and
protects it from dephosphorylation by phosphatases. Biochemical and
crystallographic analyses have revealed the molecular mechanism by
which the N-terminal fragment of TPX2 (residues 1–43) interacts with
Aurora A, and locks it in a stable active conformation, also protecting it
from dephosphorylation by PP1 phosphatase (Fig. 4A, left). Protection
from enzymatic dephosphorylation [9] occurs because the phosphate
group of Thr 288 is buried in the TPX2-bound form [10]. Interestingly,
the side chain of Cys 290 is also buried in the TPX2-bound, active
conformation of Aurora A. Furthermore, the thiol group points away
from the ATP binding side, whereas it is exposed in structures of active
Aurora A obtained in the absence of TPX2 in which CoA (Fig. 4A,
middle) or ADP (Fig. 4A, right) are bound. Based on this observation,
we next investigated whether the inhibitory effect of CoA on Aurora A
was modulated by TPX2. Dose inhibition curves of Aurora A by CoA
were generated in the presence and absence of TPX2. As shown in
Fig. 4B, the presence of the TPX2 1–43 fragment completely abrogated
the inhibitory effect of CoA on Aurora A. Moreover, pre-incubation of
Aurora A with CoA attenuated TPX2-induced kinase activation in a
DTT-sensitive manner (Fig. 4C). These findings indicate that binding of
TPX2 protects Aurora A not only from dephosphorylation of Thr 288 by
phosphatases [9], but that it also prevents covalent modification (and
therefore inhibition) by CoA.
2.7. Oxidative stress induces Aurora A CoAlation in cells
Extensive protein CoAlation is observed in mammalian cells and
tissues exposed to oxidative and metabolic stress [50]. We therefore
examined whether covalent modification of Aurora A by CoA is induced
in cells after exposure to various oxidative stresses. We exploited
HEK293/Pank1β cells, which stably overexpress pantothenate kinase 1
β (Pank1β), the major rate-limiting enzyme in CoA biosynthesis [50]. It
has been shown previously that Pank1β overexpression induces a sig-
nificant increase in CoA biosynthesis [45]. These cells are also ideal for
evaluating protein CoAlation during the cellular response to oxidative
and metabolic stress [50]. Accordingly, cells were transiently trans-
fected with plasmids encoding N-terminally FLAG-tagged Aurora A and
Aurora B, and then treated with 500 μM H2O2 prior to lysis. Im-
munoprecipitation of transiently expressed FLAG-tagged proteins fol-
lowed by immunoblotting with anti-CoA antibody revealed specific
CoAlation of Aurora A in cells after exposure to H2O2, whereas Aurora B
was poorly CoAlated (Fig. 5A). To map the site(s) of Aurora A CoAla-
tion, transiently overexpressed FLAG-Aurora A was im-
munoprecipitated from cells exposed to H2O2, processed and analysed
by LC-MS/MS. This analysis revealed a CoAlated Aurora A peptide
derived from the activation segment with the sequence TTLC290GTLD-
YLPPEMIRGR, confirming covalent modification in cells
(Supplementary Fig. S3B), and consistent with CoAlation of purified
Aurora A in vitro (Fig. 2B). Next, Aurora A CoAlation was examined in
cells exposed to a diverse range of oxidising agents. As shown in Fig. 5B,
Fig. 4. Inhibitory effect of TPX2 binding on CoA interaction with Aurora A and position of pT288. (A) Magnified views of the activation loop of Thr 288-
phosphorylated Aurora A in the crystal structures of complexes with: ADP/TPX2, PDB code 1OL5; CoA (center); or ADP, PDB code 1OL7 (right). Note that in the ADP
complex, the sulfur on the side chain of Cys 290 is not included in the experimental model but is shown here, and the β3-αC loop removed for clarity. (B) Aurora A is
resistant to inhibition by CoA in the presence of TPX2 1–43 peptide. Kinase activity of recombinant His-Aurora A was assayed by measuring incorporation of γ33P-
ATP into myelin basic protein in the presence or absence of N-terminal fragment of TPX2 (residues 1–43) and serial dilutions of CoA (C) Pre-incubation of Aurora A
with CoA inhibits TPX2-induced kinase activation in a DTT-sensitive manner.Recombinant His-Aurora A was preincubated with 100 μM CoA before the in vitro kinase
assay which was performed in the presence or absence of the N-terminal fragment of TPX2 (residues 1–43) and DTT.
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CoAlation of transiently expressed Aurora A was strongly induced in
cells treated with diamide and to a lesser extent after exposure to hy-
drogen peroxide, menadione or phenylarsine oxide (PAO). It was re-
cently reported that ROS-induced cell cycle arrest promotes hyper-
phosphorylation of Aurora A leading to abnormal mitotic spindle
assembly and significant mitotic delay [58]. Therefore, we examined
phosphorylation of Aurora A at Thr 288 by probing the same samples
with an anti-pT288 antibody. We confirmed that treatment of cells with
diamide, H2O2, menadione and PAO promoted an increase in Aurora A
phosphorylation at Thr 288 when samples were separated in the pre-
sence of the reducing agent DTT (Fig. 5C). However, when the samples
were separated under non-reducing conditions and probed with anti-
pT288 and anti-FLAG antibodies, the formation of Aurora A dimers was
clearly observed in cells treated with diamide, H2O2 and menadione
(Fig. 5C). In support of these findings, we found that brief exposure of
purified Aurora A to peroxide increased the appearance of a putative
Aurora A dimer, which was prevented by mutating Cys 290 to Ala. The
dimer was sensitive to DTT exposure, based on a comparative reducing
and non-reducing SDS-PAGE analysis (Supplementary Fig. S4). Taken
together, these results allow us to propose a simple model for regulation
of Aurora A by oxidative stress in cells (Fig. 5D). In exponentially
growing cells, Aurora A carries out many of its cellular functions by
using ATP as substrate for protein phosphorylation. The binding of CoA
to the Aurora A ATP binding pocket via the ADP moiety is effectively
outcompeted by ATP (Fig. 5D, left panel). In contrast, exposure of cells
to oxidative stress induces covalent binding of CoA to phosphorylated
Aurora A (Fig. 5D, right panel), which is accompanied by a loss of
catalytic activity and altered cell signaling.
2.8. CoA microinjection studies in mouse oocytes
To study the cell cycle effects of increased CoA in vivo, we employed
two established microinjection models. Catalytically-active Aurora A is
essential for normal spindle formation during mouse oocyte maturation
[16,71], and blocks mitotic cell cycles after Xenopus embryo micro-
injection [72,73]. Mouse oocytes arrested at the GV stage were injected
with different concentrations of CoA, and 17 h after GV release, oocytes
were fixed and stained for α-tubulin (green) and DNA (blue) to observe
effects on spindle formation, which are under the control of Aurora A.
We found that microinjection of CoA markedly increased the number of
oocytes with atypical spindles and misaligned chromosomes in a dose-
dependent manner (Fig. 6A). Our in vitro studies convincingly demon-
strated the importance of both the pantetheine tail and the 3’-phosphate
of CoA in mediating a high-affinity interaction with Aurora A (Fig. 1).
We therefore examined the effect of injected CoA, or related com-
pounds lacking different regions of the CoA molecule, to cause ab-
normal spindle formation and misalignment of chromosomes in mouse
oocytes. We found that CoA, but not pantetheine, ADP or AMP, dis-
rupted both bipolar spindle formation and chromosome alignment in
vivo (Fig. 6B). These data confirm that the pantetheine tail is required
for inhibitory spindle effects of CoA in mouse oocytes.
3. Discussion
Binding partners and post-translational modifications regulate the
pleiotropic cellular functions of Aurora A by switching it between in-
active and active conformations [74]. The intrinsic catalytic activity of
Aurora A is low prior to mitosis, and activation involves autopho-
sphorylation of Thr 288 in the activation loop, which is promoted
through interaction with microtubule-associated proteins such as TPX2
and TACC3. In this study, we identify CoA as a novel factor that binds
and inhibits Aurora A activity in vitro and in human cells, potentially as
part of the cellular response to oxidative stress. Aurora A CoAlation was
not observed in exponentially growing cells, but was significantly in-
duced after oxidative stresses. Consistently, microinjection of CoA into
mouse oocytes induced cell cycle effects, which included atypical
chromosome alignment and a failure to build a metaphase II spindle.
Fig. 5. Oxidative stress induces Aurora A CoAlation in human cells. (A) Aurora A CoAlation is induced in cellular response to H2O2. FLAG-tagged WT Aurora A
and WT Aurora B were transiently overexpressed in HEK293/Pank1β. Transfected cells were treated for 30 min with 0.25 mM H2O2. Overexpressed proteins were
immunoprecipitated with an anti-FLAG antibody and the immune complexes immunoblotted with anti-CoA and anti-FLAG antibodies. (B) Oxidising agents promote
Aurora A CoAlation in vivo. FLAG-tagged WT Aurora A was transiently over expressed in HEK293/Pank1β. Transfected cells were treated for 30 min with a panel of
oxidising agents (250 μM H2O2, 500 μM diamide, 50 μM menadione, 10 μM phenylarsine oxide and 1 μM rotenone). Transiently expressed proteins were im-
munoprecipitated with an anti-FLAG antibody, separated by SDS-PAGE under non-reducing conditions and immunoblotted with anti-CoA antibodies. (C)
Phosphorylation at Thr 288 and dimerization of Aurora A are induced in cells by oxidising agents. FLAG-tagged WT Aurora A was transiently overexpressed in
HEK293/Pank1β. Transfected cells were treated for 30 min with a panel of oxidising agents (250 μM H2O2, 500 μM diamide, 50 μM menadione, 10 μM phenylarsine
oxide and 1 μM rotenone). Transiently expressed proteins were immunoprecipitated with an anti-FLAG antibody, separated by SDS-PAGE under reducing and non-
reducing conditions and immunoblotted with anti-FLAG and anti-pT288 Aurora A antibodies. (D) Schematic illustration showing the key features of the ‘dual anchor’
mechanism for interaction of CoA with Thr 217 and Cys 290 in Aurora A.
Fig. 6. Microinjection of CoA causes abnormal spindles and chromosome
misalignment in mouse oocytes.
(A) Mouse oocytes arrested at the GV stage were injected with CoA or related
compounds, representing different determinants of the CoA molecule. 17 hrs
after GV release, cells were fixed and stained for alpha-tubulin (green) or DNA
(blue). Representative examples of control and CoA-injected oocytes are shown.
(B) The numbers of mouse oocytes with normal and abnormal spindles were
recorded. Data shown are from n=2 experiments. As a control, ~90% of
control water-injected oocytes were in possession of a normal metaphase II
bipolar spindle with aligned chromosomes. (For interpretation of the references
to color in this figure legend, the reader is referred to the Web version of this
article.)
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This phenotype is consistent with the chemical or genetic ablation of
Aurora A activity [12]. Mechanistically, Aurora A CoAlation is initiated
by anchoring the ADP moiety of CoA to the ATP-binding pocket of a
partially oxidised form of Aurora A, which involves a selectivity-de-
termining interaction between the 3′-phosphate ADP moiety of CoA and
Thr 217. Wedging of the ADP moiety then positions the flexible pan-
tetheine tail of CoA with the thiol group in close proximity for covalent
bond formation with Cys 290 in the Aurora A activation segment, two
residues C-terminal from the regulatory phosphorylated Thr 288 re-
sidue. We speculate that under oxidative stress, covalent binding of the
pantetheine thiol to Cys 290 keeps the ADP moiety firmly anchored to
the ATP binding pocket, making it inaccessible to ATP, and preventing
phosphotransferase activity. This “dual anchor” mechanism locks the
kinase in an inactive state, potentially making CoA a more potent and
selective endogenous inhibitor of Aurora A when compared to Aurora B
or other related protein kinases.
3.1. What is the biological function of Aurora A CoAlation?
In addition to an inhibitory effect on Aurora A activity, CoAlation at
Cys 290 may serve other regulatory purposes. First, CoA modification
might protect Cys 290 from over-oxidation, which may lead to an ir-
reversible loss of function and subsequent inactivation and/or de-
gradation of Aurora A. The widespread ability of CoA to act as a low-
molecular-weight antioxidant in response to oxidative and metabolic
stress in prokaryotic and eukaryotic cells has been recently demon-
strated [50,52]. In these studies, in vitro CoAlation of the catalytic Cys
151 in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
shown to protect this essential glycolytic enzyme against irreversible
over-oxidation and the associated loss of activity. It remains to be seen
whether oxidation of Cys 290 in Aurora A to sulfenic acid (which is
reversible) facilitates covalent modification by CoA via a disulfide-ex-
change mechanism, protecting this highly susceptible thiol from irre-
versible over-oxidation. Secondly, covalent modification of Cys 290 by
CoA may modulate the phosphorylation status of Thr 288, which is
critical for Aurora A catalytic activity. Previous studies reported dif-
ferential sensitivity of Thr 288 to dephosphorylation by phosphatase
complexes of the phosphoprotein phosphatase (PPP) family. An intri-
guing possibility is that redox-induced covalent linkage of CoA to Cys
290, which is directly adjacent to Thr 288, may prevent the binding of
phosphatases that control the dephosphorylation of Thr 288. In support
of this hypothesis, we found that phosphorylation of Aurora A at Thr
288 was significantly increased under oxidative stress induced by dia-
mide, H2O2, menadione and PAO. Alternative explanations for the ob-
served accumulation of phosphorylated Aurora A are possible. CoA may
act as a more efficient inhibitor of this form of the kinase or CoA
modulates the activity of Aurora A regulatory phosphatases. Ad-
ditionally, CoAlation of Aurora A might change recognition of the
protein by the Thr 288 phosphospecific antibody and make it more
readily detectable.
An involvement of CoA, a fundamental metabolic integrator in the
regulation of Aurora A, provides new insight into our understanding of
regulatory mechanisms of cell cycle progression mediated by metabolic
adaptation to oxidative stress. Energy flow and biosynthetic processes
are tightly regulated during the cell cycle. CoA plays a critical role in
generating a diverse range of metabolically active thioester derivatives
(including Acetyl-CoA, HMG-CoA, Malonyl-CoA and Acyl-CoA), which
function as driving forces for generating ATP, the biosynthesis of
macromolecules and the regulation of gene expression via protein
acetylation. The presence of a highly reactive thiol group in CoA and its
potential involvement in redox regulation has intrigued researchers for
many decades, but progress in this field of study has been hampered by
a lack of precise research tools and methodologies. Our findings are
consistent with novel functions of CoA in cellular response to oxidative
and metabolic stress, which involves covalent attachment of this
coenzyme to redox-sensitive Cys residues [50]. Protein CoAlation is
therefore emerging as an important post-translational modification
implicated in redox regulation of a diverse range of proteins [44], in-
cluding redox-controlled protein kinases [75].
Our work also demonstrates a hitherto unappreciated CoAlation of
Aurora A during cellular response to oxidative stress. This mechanism
of regulation may thus be relevant to other members of the human
kinome that possess Cys residues in the activation segment, or else-
where [76,77]. This includes other basophilic Ser/Thr kinases such as
PKA, although PKA inhibition by CoA was not detected in vitro. How-
ever, the reversible glutathionylation of Cys 199, equivalent to Cys 290
in Aurora A, has previously been demonstrated [78], and correlates
with functional Cys 199 redox status in controlling T-loop phosphor-
ylation at the adjacent Thr 197 site in PKA, equivalent to Thr 288 in
Aurora A [79,80]. In addition to Aurora A, CoA also modestly inhibited
several unrelated protein kinases, including SRC, YES, BTK and FGFR1
(Table 1). However, none of these tyrosine kinases contain a Cys re-
sidue in the activation segment. It remains to be observed whether
covalent modification of tyrosine kinases by CoA occurs in cells, and if
so, whether it is also induced by oxidative stress. In the case of CoA, our
data suggest that the “dual anchor” inhibitory mechanism in Aurora A
permits precise spatial communication between the ATP-binding site
and the activation loop, explaining the very high degree of specificity
for CoAlation of Aurora A and preventing a high-affinity interaction
even towards very closely-related kinases, such as Aurora B.
4. Conclusion
Our findings raise the interesting possibility that new covalent ap-
proaches can be developed to target Aurora A, or other kinases pos-
sessing Cys residues in the activation segment, with small inhibitory
molecules. This dual targeting mechanism might be the basis of a new
approach for design of specific, and potentially irreversible, Aurora A
small molecule inhibitors, with long-time target engagement in cells.
The majority of protein kinase (including Aurora A) inhibitors are
currently ATP competitive (non-covalent) inhibitors, which are de-
signed to gain at-least some selectivity through the recognition of un-
ique features of conformation-specific ATP-binding pockets. However,
there has been a resurgence of interest in generating covalent com-
pounds targeting Cys residues in drug targets, most notably RAS [81],
previously considered undruggable. Moreover, biochemical tool com-
pounds [82,83] and clinical inhibitors covalently targeting oncogenic
kinase, are enjoying significant clinical success [84]. However, one of
the liabilities of such compounds is the appearance of drug resistance,
caused by point mutations in the Cys residue at the covalent drug in-
terface. In this study, we report a new ‘dual-mode’ of Aurora A in-
hibition by the metabolic integrator CoA, which also reveals how spe-
cific targeting of kinases might be accomplished with a distinct class of
irreversible inhibitor, whose ability to covalently trap kinases in an
inhibitory conformation could represent a new type of redox-mediated
approach to tuning signaling outputs.
5. Materials and methods
5.1. Reagents and chemicals
The generation and characterization of the monoclonal anti-CoA
antibody 1F10 has been described previously [50]. All common che-
micals and biochemicals were obtained from Sigma-Aldrich unless
otherwise stated, including CoA, dpCoA, dsCoA, ATP, and ADP. The
following antibodies were employed: mouse anti-CoA antibody; mouse
anti-FLAG M2 antibody (Sigma-Aldrich); rabbit anti-Aurora A and anti-
Aurora B antibodies (Merck-Millipore); rabbit anti-pT288 Aurora A
(Cell Signaling Technology), Alexa Fluor 680 goat anti-mouse IgG H&L
(Life Technologies) and IRdye 800 CW goat anti-rabbit IgG H&L (LI-
COR Biosciences).
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5.2. Kinase profiling screen and Aurora A IC50 determination
Profiling of 117 protein kinases with CoA, dpCoA and ADP was
carried out at the International Centre for Protein Kinase Profiling at
the University of Dundee. Each compound was tested in vitro, in du-
plicate, at 100 μM final concentration using recombinant kinases,
model substrates and optimal concentrations of ATP. Bacterially ex-
pressed full-length His-Aurora A was used to determine the IC50 value
for CoA (in the presence or absence of DTT), dpCoA, ADP and desulfo-
CoA. The assay was performed in the presence of 5 μM competing ATP.
To examine whether the inhibitory effect of CoA on Aurora A is
modulated by TPX2, IC50 values for CoA were also generated in the
presence and absence of 1 μg TPX2 (residues 1–43) fragment.
5.3. In vitro Aurora A kinase assay
Aurora A kinase activity was assayed by measuring incorporation of
γ33P-ATP into myelin basic protein (Sigma). Purified recombinant
protein (100 ng) was incubated at room temperature for 30 min in a
total volume of 15 μl containing 50 mM HEPES pH 7.5, 10 mMMgCl2, 1
mM EGTA, 0.05% Brij-35, 0.5mg/ml myelin basic protein, and 5 μM
γ33P-ATP (100–10,000 dpm/pmol). The reaction was stopped by spot-
ting the reaction mixture onto squares of P81 phosphocellulose ion
exchange paper (Whatmann), which were then immersed in 1.5% (v/v)
phosphoric acid. After washing twice in 1% phosphoric acid followed
by two washes in distilled water, the papers were air dried and radio-
activity was counted by a scintillation counter and recorded by
Quantasmart version 2.03.
5.4. In vitro CoAlation assay
For CoAlation assays, 0.5 μg of purified recombinant preparations of
wild type and mutant forms of His-Aurora A (Cys290Ala; Cys393Ala,
Cys290/393Ala, Thr217Glu) and His-Aurora B (Glu161Thr) were in-
cubated with a mixture of oxidised and reduced forms of CoA (CoASH
and CoASSCoA, 1 mM final) in 20 mM Tris-HCl, pH 7.5 for 30 min at
RT. The reaction was stopped by adding SDS gel-loading buffer without
DTT, but containing 10 mM NEM. To examine whether binding of the
3′-phosphate ADP moiety of CoA to the Aurora A ATP binding-pocket
co-ordinates the pantetheine thiol for disulfide bond formation with Cys
290, the in vitro CoAlation assay was carried out with 100 μM CoA and
increasing concentrations of ATP (0–10 mM).
5.5. CoA Sepharose pull-down assay
Exponentially growing HepG2 cells were lysed on ice in buffer,
containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM ethylenedia-
minetetraacetic acid (EDTA), 50 mM sodium fluoride (NaF), 5 mM
tetra-sodium pyrophosphate (Na4P2O7) and 1% (v/v) Triton X-100,
supplemented with 1x Protease Inhibitor Cocktail (PIC, Roche). After
centrifugation, the supernatant was incubated on a rotating wheel with
CoA Sepharose or Sepharose alone for 2h at 4 °C. Beads were then
washed extensively with lysis buffer and bound proteins were eluted
from beads with 2x SDS loading buffer. To elute proteins that bound
specifically to CoA Sepharose, the cell lysis buffer was supplemented
with 100 μM CoA (CoA eluted fraction). Eluted proteins were separated
by SDS-PAGE and Western blotted with anti-Aurora A antibody.
5.6. Lanthascreen Eu Kinase FRET binding assay
A Lanthascreen Eu Kinase FRET Binding Assay (Invitrogen) was
employed to determine IC50 values for the interaction of Aurora A with
CoA, dpCoA, ATP, and ADP. In this assay, we used bacterially expressed
His-Aurora A in active and inactive (PP1-treated, pT288 depho-
sphorylated) states. Recombinant Aurora A was incubated with
Europium-conjugated anti-histidine tag antibody and an Alexa Fluor
647-labelled tracer, which binds to the ATP binding pocket of Aurora A.
The close proximity of the anti-histidine (epitope-tag) antibody and the
tracer results in a high degree of FRET (fluorescence resonance energy
transfer) from the europium donor fluorophore to the Alexa Fluor 647
acceptor fluorophore. ATP-competitive inhibitors, such as CoA, displace
the tracer from the active site, causing a loss of FRET signal. Assay set-
up was performed as described by the manufacturer. Briefly, the time-
resolved fluorescence resonance energy transfer assay (TR-FRET) was
performed in black, low volume 384 well plates (Corning). Each well
contained 5 nM kinase, 2 nM Eu-anti-His antibody and 10 nM kinase
tracer 236 in kinase buffer A (50 mM Hepes pH 7.5, 10 mM MgCl2, 1
mM EDTA, 0.01% (v/v) Brij-35), varying amounts of CoA, dpCoA, ATP,
and ADP. The reaction mix was incubated for 1h at room temperature.
The signal was measured at 665/620 nm emission ratio using BMG
LABTECH plate reader (PHERAstar). All assays were performed using
duplicates. The 11-point response curves were generated using
GraphPad Prism software from the inhibition data generated.
5.7. Plasmids and protein purification for differential scanning fluorimetry
(DSF)
For enzyme and DSF assays, full-length human Aurora A and Aurora
B and 1–43 TPX2 were produced in BL21 (DE3) pLysS E. coli cells
(Novagen) with expression induced with 0.5mM IPTG for 18h at 18 °C
and purified as N-terminal 6His-tag fusion proteins by immobilized
metal affinity chromatography (IMAC) and size exclusion chromato-
graphy using a HiLoad 16/600 Superdex 200 column (GE Healthcare)
equilibrated in 50 mM Tris/HCl, pH 7.4, 100 mM NaCl, 10 % (v/v)
glycerol and 1 mM DTT. Asp274Asn and Thr217Glu Aurora A mutants
were generated by PCR-site directed mutagenesis, expressed and pur-
ified as described previously [40]. Cys290Ala Aurora A was generated
using standard procedures, and purified as described.
5.8. Differential scanning fluorimetry
Thermal-shift assays were performed with a StepOnePlus Real-Time
PCR machine (Life Technologies) using Sypro-Orange dye (Invitrogen)
and thermal ramping (0.3 °C in step intervals between 25 and 94 °C).
All proteins were diluted to a final concentration of 5 μM in 50 mM
Tris/HCl, pH 7.4 and 100 mM NaCl in the presence or absence of the
indicated concentrations of ligand (final DMSO concentration no higher
than 4 % v/v). CoA, dephosphoCoA or kinase inhibitors diluted from 10
mM DMSO stocks [59] were assayed as described previously [60].
Normalized data were processed using the Boltzmann equation to
generate sigmoidal denaturation curves, and average Tm/ΔTm values
calculated as previously described [61] using GraphPad Prism software.
5.9. Molecular docking
Docking of CoA in the crystal structure of Aurora A kinase (PDB_ID:
1OL7) [10] was carried out using CDOCKER (Discovery Studio 3.1,
Accelrys Inc). In the crystal structure, a 7 Å grid was selected around
the ATP binding site in order to define the location of probable CoA
binding site. Twenty-five conformations of CoA were generated and ten
docking poses were analysed.
5.10. Crystallization and structure determination of the Aurora A
122–403/CoA complex
Aurora A (amino acids 122–403) was produced as described in
earlier work [62]. The kinase was subject to size exclusion chromato-
graphy on a HiLoad 16/600 Superdex 200 pg column (GE Healthcare)
equilibrated in 20 mM Tris pH 7.0, 0.2 M NaCl, 5 mM MgCl2, 10 % (v/
v) glycerol prior to crystallization trials. Aurora A was concentrated to
16.5 mg/ml and incubated with 5 mM CoA for 30 min at 30 °C. Crys-
tallization screens were laid down in 96-well MRC plates using a
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Mosquito LCP crystallization robot (TTP Labtech) and incubated at
295 K. Crystals were produced in 0.03 M MgCl2·6H20, 0.03 M
CaCl2·2H20, 0.1 M MOPS/HEPES-Na pH 7.5, 20 % (v/v) PEG 500 MME,
10 % (w/v) PEG 20 000 (Molecular Dimensions) and flash frozen di-
rectly from the drop.
X-ray diffraction data were collected on beamline I03 at Diamond
Light Source, Oxford, England from a single crystal. Data processing
was performed by the xia2 3dii automated data-reduction platform at
Diamond [63]. The structure of the complex was solved by molecular
replacement using Phaser-MR [64] and the structure of Aurora A
122–403 C290A, C393A (PDB 4CEG) as a model [65]. Phenix.refine
was used to solve the structure and carry out iterative refinement [66].
Model building was performed using Coot [67]. Structure validation
and data quality were determined by Molprobity [68].
5.11. Human cell culture
HEK293 and HEK293/Pank1β cells were cultured in Dulbecco's
Modified Eagle Medium (DMEM) (Lonza) supplemented with 10%
foetal bovine serum (FBS) (Hyclone), 50 U/ml penicillin and 0.25 μg/
ml streptomycin (Lonza). HepG2 cells were cultured in Williams E
media (Lonza) supplemented with 10 % FBS, 50 U/ml penicillin and
0.25 μg/ml streptomycin. All cell lines were tested and shown to be free
of mycoplasma infection. Generation of HEK293/Pank1β cell line with
stable overexpression of Pantothenate kinase 1β was previously re-
ported [50].
5.12. Transient transfection of HEK293/PANK1β cells and treatment with
oxidising agents
HEK293/Pank1β cells were transfected at ~60% confluence with
pCMV6-Entry/FLAG-Aurora A and pCMV6-Entry/FLAG-Aurora B plas-
mids, according to the manufacturer's protocol using Turbofect reagent
(Thermo Scientific). Transfected cells were allowed to grow for 24 h in
complete DMEM with 10 % FBS. The medium was replaced with pyr-
uvate-free DMEM supplemented with 5 mM glucose and 10 % FBS and
cells were incubated for another 24 h. Pyruvate was removed from the
media because it can act as an antioxidant and inactivate ROS. Cells
were then treated with H2O2 (250 μM), menadione (50 μM), pheny-
larsine oxide (PAO, 10 μM), diamide (500 μM) or rotenone (1 μM) for
30 min at 37 °C in pyruvate-free DMEM supplemented with 5 mM
glucose. Cells were harvested by pressure washing and centrifuged at
1800 g for 5 min at RT.
5.13. Cell lysis, immunoprecipitation and western blot analysis
Harvested cells were lysed at 4 °C for 20 min in lysis buffer, con-
taining 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 50 mM
NaF, 5 mM Na4P2O7 and 1 % Triton X-100, supplemented with fresh
100 mM NEM and fresh 1x PIC. Total cell lysates were centrifuged at
20817×g for 10 min at 4 °C and the supernatant was collected for
further analysis. Protein concentration was measured using the
Bicinchoninic acid Protein Assay Kit (Thermo Scientific).
Immunoprecipitation of transiently expressed FLAG-Aurora A and
FLAG-Aurora B from cell lysates was carried out using Protein G
Sepharose (Generon) and anti-FLAG antibody (Sigma-Aldrich). Proteins
were eluted from beads with 2x SDS loading buffer and separated by
SDS-PAGE under non-reducing conditions. Resolved proteins were
transferred to a PVDF membrane (Bio-Rad Laboratories), which was
then blocked with Odyssey blocking buffer. The membrane was in-
cubated in anti-CoA or anti-FLAG antibodies for 2 h at room tempera-
ture (RT) or overnight at 4 °C, and then with secondary antibodies for
30 min (RT). Immunoreactive bands were visualised using Odyssey
Scanner CLx and Image Studio Lite software (LI-COR Biosciences).
5.14. Microinjection of mouse oocytes
Mouse oocytes arrested at the GV stage were injected with different
concentrations of CoA (0.15–5 mM). Since the commercial preparation
of CoA used for microinjection contained 3 mol of lithium ions per mole
of CoA, control oocytes were injected with an equivalent amount of
LiCl. In a separate study, oocytes were injected with 3 mM CoA, ADP,
AMP, 3′-5′-ADP and pantetheine. To examine the effect of injected
compounds on spindle formation, oocytes were fixed 17 h after GV
release and stained for alpha-tubulin (green) and DNA (blue).
5.15. Intact mass spectrometry
To generate CoA or dPCoA complexes with Aurora A, 10 μM WT
Aurora A was incubated with 100 μM CoA or dpCoA for 15 min at room
temperature. To evaluate the interaction, intact complexes were de-
salted using a C4 desalting trap (Waters MassPREP™ Micro desalting
column, 2.1× 5 mm, 20 μm particle size, 1000 Å pore size). Aurora A
was eluted with 50 % (v/v) MeCN, 0.1 % (v/v) formic acid. Intact mass
analysis was performed using a Waters nano ACQUITY Ultra
Performance liquid chromatography (UPLC) system coupled to a
Waters SYNAPT G2, as described [60]. Samples were eluted from a C4
trap column at a flow rate of 10 μL/min using three repeated 0–100 %
acetonitrile gradients. Data was collected between 400 and 3500m/z
and processed using MaxEnt1 (maximum entropy software, Waters
Corporation).
5.16. Ion mobility
IM-MS analysis was performed on a Waters Synapt G2-Si instru-
ment. Purified Aurora A was buffer exchanged into 50 mM NH4OAc (LC
grade, Sigma) as previously described [69]. Typically, 1–3 μl of 2–5 μM
sample was analysed using borosilicate emitters (Thermo ES 387).
Spraying voltage was adjusted to 1.1–1.8 kV, sampling cone was 20 V.
Pressure in the travelling wave (T-wave) ion mobility cell was
2.78mbar (nitrogen), wave height was kept at 30 V, wave velocity at
750m/s. In order to experimentally determine collision cross section
(CCS), drift time through the T-wave mobility cell was performed using
β-lactoglobulin A (Sigma L7880), avidin (Sigma A9275), transthyretin
(Sigma P1742), concanavalin A (Sigma C2010) and serum albumin
(Sigma P7656) according to standard protocols. The exact hard sphere
scattering (EHSS) model implemented in the Mobcal software was used
to calculate CCS values on the basis of X-ray structures, as described
previously [69].
5.17. Mass spectrometry and data processing
In vitro CoAlated His-Aurora A or immunoprecipitated FLAG-Aurora
A were digested with sequencing grade trypsin (Promega). After heat-
inactivation of trypsin, CoAlated peptides were immunoprecipitated
with anti-CoA antibody cross-linked to Protein G Sepharose.
Immunoprecipitated peptides were treated with Nudix 7 and enriched
further by an IMAC column before LC–MS/MS analysis. The resulting
samples were analysed by nano-scale capillary LC-MS/MS using an
Ultimate U3000 UPLC System (Dionex) fitted with a 100 μm×2 cm
PepMap100 C18 nano trap column and a 75 μm×25 cm PepMap100
C18 nano analytical column (Dionex). Peptides were eluted using an
acetonitrile gradient and sprayed directly via a nano-flow electrospray
ionization source into the mass spectrometer (Orbitrap Velos, Thermo
Scientific). The mass spectrometer was operated in data dependent
mode, using a full scan (m/z=350–1600) in the Orbitrap analyser,
with a resolution of 60 000 at m/z= 400, followed by MS/MS acqui-
sitions of the 20 most intense ions in the LTQ Velos ion trap. Maximum
FTMS scan accumulation times were set at 250ms and maximum ion
trap MSn scan accumulation times were set at 200ms. The Orbitrap
measurements were internally calibrated using the lock mass of
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polydimethylcyclosiloxane at m/z 445.120025. Dynamic exclusion was
set for 30 s with exclusion list of 500. LC-MS/MS raw data files were
processed as standard samples using MaxQuant [70] version 1.5.2.8,
which incorporates the Andromeda search engine. MaxQuant processed
data was searched against Human UniProt protein database. Carbami-
domethyl cysteine, Acetyl N-terminal, N-ethylmaleimide cysteine, oxi-
dation of methionines, CoAlation of cysteine with delta mass 338, 356
and 765, were set as variable modifications. For all data sets, the default
parameters in MaxQuant were used, except MS/MS tolerance, which
was set at 0.6 Da and the second peptide ID was unselected.
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